Executive Search Firm Informs Readers of 2024 Projected Market Increase Spending for Vasculitis to Reach Upwards of $588 Million
Berke Executive Search, an expert biotech executive search firm, discusses a report with market projections for Vasculitis - a condition involving inflammation of the blood vessels - is expected to reach upwards of $588 million by 2024. This is up from the $342 million in 2014, with a compound annual growth rate (CAGR) of 5.1 percent.
Philadelphia, PA, February 25, 2016 --(PR.com)-- According to the GlobalData, a report released in January 2016, the projected growth is due to the anticipated launch of five new biologics for the treatment of Vasculitis. These biologics offer exciting new prospects for drug companies through more effective treatment of the condition and lack of inconvenient side effects. The new biologics expected to be released include:
• Actemra - released by Roche
• Benlysta - released by GlaxoSmithKline (GSK)
• Nucala - released by GlaxoSmithKline (GSK)
• Orencia - released by Bristol-Myers Squibb (BMS)
• Remicade - released by Johnson & Johnson
Of the five new treatment options, three stand out as likely to be the most successful due to the strong effectiveness in treating Vasculitis and the lack of unpleasant side effects during clinical trials. The biologics expected to be the most successful are:
• Bristol-Myers Squibb's Orencia
• GlaxoSmithKline's Nucala
• Roche's Actemra
Despite projections of an increase spending in order to treat Vasculitis, Immunology Analyst at Global Data, Alexandra Annis, has been quoted as saying, "The high cost of biologics will limit their uptake, especially in cost-conscious markets that are facing austerity measures."
Despite the barriers, the treatment market for Vasculitis remains an attractive area for the pharmaceutical industry because of the current lack of options that provide effective treatment with minimal side effects.
About Berke Executive Search
Berke Executive Search is a leading pharmaceutical and biotech executive search firm, specializing in the assessment and recruitment of talent acquisitions for the pharmaceutical and biotech industries. Berke's team of experts ensures that each biotech executive search exceeds clients' expectations and contributes to the growth of their business. Experts at Berke are committed to keeping up with the latest healthcare industry trends so they can keep their clients and audience informed of recent developments and news.
For more information, please call (267) 483-8951 of visit www.berkeseach.com.
• Actemra - released by Roche
• Benlysta - released by GlaxoSmithKline (GSK)
• Nucala - released by GlaxoSmithKline (GSK)
• Orencia - released by Bristol-Myers Squibb (BMS)
• Remicade - released by Johnson & Johnson
Of the five new treatment options, three stand out as likely to be the most successful due to the strong effectiveness in treating Vasculitis and the lack of unpleasant side effects during clinical trials. The biologics expected to be the most successful are:
• Bristol-Myers Squibb's Orencia
• GlaxoSmithKline's Nucala
• Roche's Actemra
Despite projections of an increase spending in order to treat Vasculitis, Immunology Analyst at Global Data, Alexandra Annis, has been quoted as saying, "The high cost of biologics will limit their uptake, especially in cost-conscious markets that are facing austerity measures."
Despite the barriers, the treatment market for Vasculitis remains an attractive area for the pharmaceutical industry because of the current lack of options that provide effective treatment with minimal side effects.
About Berke Executive Search
Berke Executive Search is a leading pharmaceutical and biotech executive search firm, specializing in the assessment and recruitment of talent acquisitions for the pharmaceutical and biotech industries. Berke's team of experts ensures that each biotech executive search exceeds clients' expectations and contributes to the growth of their business. Experts at Berke are committed to keeping up with the latest healthcare industry trends so they can keep their clients and audience informed of recent developments and news.
For more information, please call (267) 483-8951 of visit www.berkeseach.com.
Contact
Berke Executive Search
Carl Berke
267-483-8951
www.berkesearch.com
Carl Berke
267-483-8951
www.berkesearch.com
Contact
Categories